Aspire Private Capital’s Freeline Therapeutics Holdings FRLN Stock Holding History
Bought
Maintained
Sold
Aspire Private Capital's FRLN Position: Q1 2024 in Review
Aspire Private Capital sold out of Freeline Therapeutics Holdings (FRLN) in Q1 2024, closing a stake of 80 shares — an estimated $509 sold.
Aspire Private Capital first reported a position in FRLN in Q1 2022 and held it in 8 quarters. The position peaked at $1K in Q3 2022. 0 funds tracked by Wall St. Rank hold FRLN as of Q1 2024.
- Aspire Private Capital reported no remaining Freeline Therapeutics Holdings position as of Q1 2024 after selling out during the quarter.
- Aspire Private Capital sold 80 Freeline Therapeutics Holdings shares in Q1 2024, an estimated $509.
- Aspire Private Capital first reported a position in Freeline Therapeutics Holdings in Q1 2022 and held it in 8 quarters.
- Aspire Private Capital's Freeline Therapeutics Holdings position peaked at $1K in Q3 2022.
- 0 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings as of Q1 2024.
Based on Aspire Private Capital's 13F filing for Q1 2024, filed 18 Apr 2024.